The reason for that is that the influenzavirus has a rapid rate of mutation, forcing companies that manufacture the vaccine to make their best guess as to which flu types will be more prevalent in a given season.
As of January 5, the CDC said Friday, the predominant virus in the United States was an influenzaA (H3N2) virus that matched well with the H3N2 virus represented in the vaccine.